{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:35:23Z","timestamp":1707525323844},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,15]]},"DOI":"10.7759\/cureus.47057","type":"journal-article","created":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T11:23:24Z","timestamp":1697369004000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Steroid-Resistant Nodular Episcleritis With Tacrolimus: A Case Report"],"prefix":"10.7759","author":[{"given":"Ali H","family":"Alghamdi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90157-4","article-title":"Severity of episcleritis and systemic disease association","volume":"106","author":"Akpek EK","year":"1999","unstructured":"Akpek EK, Uy HS, Christen W, Gurdal C, Foster CS. Severity of episcleritis and systemic disease association. Ophthalmology. 1999, 106:729-31. 10.1016\/S0161-6420(99)90157-4","journal-title":"Ophthalmology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.07.013","article-title":"Clinical characteristics of a large cohort of patients with scleritis and episcleritis","volume":"119","author":"Sainz de la Maza M","year":"2012","unstructured":"Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, Priyanka P, Tauber J, Foster CS. Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology. 2012, 119:43-50. 10.1016\/j.ophtha.2011.07.013","journal-title":"Ophthalmology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2011-130282","article-title":"Scleritis: presentations, disease associations and management","volume":"88","author":"Sims J","year":"2012","unstructured":"Sims J. Scleritis: presentations, disease associations and management. Postgrad Med J. 2012, 88:713-8. 10.1136\/postgradmedj-2011-130282","journal-title":"Postgrad Med J"},{"key":"ref4","article-title":"Albert and Jakobiec's Principles and Practice of Ophthalmology","author":"Albert DM","year":"2008","unstructured":"Albert DM, Jakobiec FA. Albert and Jakobiec's Principles and Practice of Ophthalmology. Albert DM, Miller JW, Azar DT, Young LH (ed): Saunders, Philadelphia, PA; 2008."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31816576ef","article-title":"Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort","volume":"28","author":"French DD","year":"2008","unstructured":"French DD, Margo CE. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina. 2008, 28:889-93. 10.1097\/IAE.0b013e31816576ef","journal-title":"Retina"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.60.3.163","article-title":"Scleritis and episcleritis","volume":"60","author":"Watson PG","year":"1976","unstructured":"Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol. 1976, 60:163-91. 10.1136\/bjo.60.3.163","journal-title":"Br J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(94)31325-x","article-title":"Severity of scleritis and episcleritis","volume":"101","author":"Sainz de la Maza M","year":"1994","unstructured":"Sainz de la Maza M, Jabbur NS, Foster CS. Severity of scleritis and episcleritis. Ophthalmology. 1994, 101:389-96. 10.1016\/s0161-6420(94)31325-x","journal-title":"Ophthalmology"},{"key":"ref8","article-title":"Episcleritis","author":"Schonberg S","year":"2023","unstructured":"Schonberg S, Stokkermans TJ. Episcleritis. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2016.1185527","article-title":"Clinical spectrum of HLA-B27-associated ocular inflammation","volume":"25","author":"Pathanapitoon K","year":"2017","unstructured":"Pathanapitoon K, Dodds EM, Cunningham ET Jr, Rothova A. Clinical spectrum of HLA-B27-associated ocular inflammation. Ocul Immunol Inflamm. 2017, 25:569-76. 10.1080\/09273948.2016.1185527","journal-title":"Ocul Immunol Inflamm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4166\/kjg.2019.73.5.269","article-title":"Ophthalmologic manifestation of inflammatory bowel disease: a review","volume":"73","author":"Lee DH","year":"2019","unstructured":"Lee DH, Han JY, Park JJ, Cheon JH, Kim M. Ophthalmologic manifestation of inflammatory bowel disease: a review. Korean J Gastroenterol. 2019, 73:269-75. 10.4166\/kjg.2019.73.5.269","journal-title":"Korean J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13761","article-title":"Epidemiology of episcleritis and scleritis in urban Australia","volume":"48","author":"Thong LP","year":"2020","unstructured":"Thong LP, Rogers SL, Hart CT, Hall AJ, Lim LL. Epidemiology of episcleritis and scleritis in urban Australia. Clin Exp Ophthalmol. 2020, 48:757-66. 10.1111\/ceo.13761","journal-title":"Clin Exp Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0420.2001.079001076.x","article-title":"Recurrent episcleritis associated with brucellosis","volume":"79","author":"G\u00fcng\u00f6r K","year":"2001","unstructured":"G\u00fcng\u00f6r K, Bekir NA, Namiduru M. Recurrent episcleritis associated with brucellosis. Acta Ophthalmol Scand. 2001, 79:76-8. 10.1034\/j.1600-0420.2001.079001076.x","journal-title":"Acta Ophthalmol Scand"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.111752","article-title":"Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study","volume":"184","author":"Etminan M","year":"2012","unstructured":"Etminan M, Forooghian F, Maberley D. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. CMAJ. 2012, 184:431-4. 10.1503\/cmaj.111752","journal-title":"CMAJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(03)00090-3","article-title":"Multifocal nodular episcleritis and scleritis with undiagnosed Hodgkin's lymphoma","volume":"110","author":"Thakker MM","year":"2003","unstructured":"Thakker MM, Perez VL, Moulin A, Cremers SL, Foster CS. Multifocal nodular episcleritis and scleritis with undiagnosed Hodgkin's lymphoma. Ophthalmology. 2003, 110:1057-60. 10.1016\/S0161-6420(03)00090-3","journal-title":"Ophthalmology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000394","article-title":"Clinical features of patients with episcleritis and scleritis in an Italian tertiary care referral center","volume":"24","author":"Berchicci L","year":"2014","unstructured":"Berchicci L, Miserocchi E, Di Nicola M, La Spina C, Bandello F, Modorati G. Clinical features of patients with episcleritis and scleritis in an Italian tertiary care referral center. Eur J Ophthalmol. 2014, 24:293-8. 10.5301\/ejo.5000394","journal-title":"Eur J Ophthalmol"},{"key":"ref16","article-title":"Kanski\u2019s Clinical Ophthalmology: A Systematic Approach","author":"Kanski JJ","year":"2015","unstructured":"Kanski JJ, Bowling B. Kanski\u2019s Clinical Ophthalmology: A Systematic Approach. Saunders, Philadelphia, PA; 2015."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2016.06.002","article-title":"Treatment and management of scleral disorders","volume":"61","author":"Daniel Diaz J","year":"2016","unstructured":"Daniel Diaz J, Sobol EK, Gritz DC. Treatment and management of scleral disorders. Surv Ophthalmol. 2016, 61:702-17. 10.1016\/j.survophthal.2016.06.002","journal-title":"Surv Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/11206721211052879","article-title":"A case of nodular episcleritis mimicking a solitary giant episcleral mass","volume":"33","author":"Zhou L","year":"2023","unstructured":"Zhou L, Wang J, Xu G, Wang D, Wang X, Chen Z. A case of nodular episcleritis mimicking a solitary giant episcleral mass. Eur J Ophthalmol. 2023, 33:10.1177\/11206721211052879","journal-title":"Eur J Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2013.854394","article-title":"Clinical characteristics of scleritis and episcleritis: results from the Pacific ocular inflammation study","volume":"22","author":"Homayounfar G","year":"2014","unstructured":"Homayounfar G, Borkar DS, Tham VM, Nardone N, Acharya NR. Clinical characteristics of scleritis and episcleritis: results from the Pacific ocular inflammation study. Ocul Immunol Inflamm. 2014, 22:403-4. 10.3109\/09273948.2013.854394","journal-title":"Ocul Immunol Inflamm"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.798998","article-title":"Incremental concentrations of tacrolimus eye drops as a strategy for the management of severe vernal keratoconjunctivitis","volume":"13","author":"Albarry MA","year":"2022","unstructured":"Albarry MA, Parekh M, Ferrari S, Eltahir HM, Shehata AM, Shaker MA, Elbadawy HM. Incremental concentrations of tacrolimus eye drops as a strategy for the management of severe vernal keratoconjunctivitis. Front Pharmacol. 2022, 13:798998. 10.3389\/fphar.2022.798998","journal-title":"Front Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701632","article-title":"A randomised, double-blind trial of topical ketorolac vs artificial tears for the treatment of episcleritis","volume":"19","author":"Williams CP","year":"2005","unstructured":"Williams CP, Browning AC, Sleep TJ, Webber SK, McGill JI. A randomised, double-blind trial of topical ketorolac vs artificial tears for the treatment of episcleritis. Eye (Lond). 2005, 19:739-42. 10.1038\/sj.eye.6701632","journal-title":"Eye (Lond)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2006.01225.x","article-title":"Biologic therapies for inflammatory eye disease","volume":"34","author":"Lim L","year":"2006","unstructured":"Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Exp Ophthalmol. 2006, 34:365-74. 10.1111\/j.1442-9071.2006.01225.x","journal-title":"Clin Exp Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702367","article-title":"Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis","volume":"21","author":"Nivenius E","year":"2007","unstructured":"Nivenius E, van der Ploeg I, Jung K, Chryssanthou E, van Hage M, Montan PG. Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis. Eye (Lond). 2007, 21:968-75. 10.1038\/sj.eye.6702367","journal-title":"Eye (Lond)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(02)01982-7","article-title":"Topical tacrolimus treatment of atopic eyelid disease","volume":"135","author":"Rikkers SM","year":"2003","unstructured":"Rikkers SM, Holland GN, Drayton GE, Michel FK, Torres MF, Takahashi S. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol. 2003, 135:297-302. 10.1016\/s0002-9394(02)01982-7","journal-title":"Am J Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e318243f69d","article-title":"Tacrolimus ointment 0.03% for treatment of refractory childhood phlyctenular keratoconjunctivitis","volume":"31","author":"Kymionis GD","year":"2012","unstructured":"Kymionis GD, Kankariya VP, Kontadakis GA. Tacrolimus ointment 0.03% for treatment of refractory childhood phlyctenular keratoconjunctivitis. Cornea. 2012, 31:950-2. 10.1097\/ICO.0b013e318243f69d","journal-title":"Cornea"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-200403000-00013","article-title":"Kaposi varicelliform eruption associated with 0.1% tacrolimus ointment treatment in atopic blepharitis","volume":"23","author":"Miyake-Kashima M","year":"2004","unstructured":"Miyake-Kashima M, Fukagawa K, Tanaka M, et al.. Kaposi varicelliform eruption associated with 0.1% tacrolimus ointment treatment in atopic blepharitis. Cornea. 2004, 23:190-3. 10.1097\/00003226-200403000-00013","journal-title":"Cornea"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.097428","article-title":"Tacrolimus immunosuppression in high-risk corneal grafts","volume":"91","author":"Joseph A","year":"2007","unstructured":"Joseph A, Raj D, Shanmuganathan V, Powell RJ, Dua HS. Tacrolimus immunosuppression in high-risk corneal grafts. Br J Ophthalmol. 2007, 91:51-5. 10.1136\/bjo.2006.097428","journal-title":"Br J Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02933.x","article-title":"Dramatic improvement of atopic keratoconjunctivitis after topical treatment with tacrolimus ointment restricted to the eyelids","volume":"23","author":"Zribi H","year":"2009","unstructured":"Zribi H, Descamps V, Hoang-Xuan T, Crickx B, Doan S. Dramatic improvement of atopic keratoconjunctivitis after topical treatment with tacrolimus ointment restricted to the eyelids. J Eur Acad Dermatol Venereol. 2009, 23:489-90. 10.1111\/j.1468-3083.2008.02933.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2.7.1167","article-title":"Topical tacrolimus for the treatment of inflammatory skin diseases","volume":"2","author":"Assmann T","year":"2001","unstructured":"Assmann T, Homey B, Ruzicka T. Topical tacrolimus for the treatment of inflammatory skin diseases. Expert Opin Pharmacother. 2001, 2:1167-75. 10.1517\/14656566.2.7.1167","journal-title":"Expert Opin Pharmacother"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S99157","article-title":"Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis","volume":"10","author":"Shoughy SS","year":"2016","unstructured":"Shoughy SS, Jaroudi MO, Tabbara KF. Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis. Clin Ophthalmol. 2016, 10:643-7. 10.2147\/OPTH.S99157","journal-title":"Clin Ophthalmol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90124-h","article-title":"Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes","volume":"66","author":"Liu J","year":"1991","unstructured":"Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991, 66:807-15. 10.1016\/0092-8674(91)90124-h","journal-title":"Cell"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.135.5.574","article-title":"Tacrolimus: the drug for the turn of the millennium?","volume":"135","author":"Ruzicka T","year":"1999","unstructured":"Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium?. Arch Dermatol. 1999, 135:574-80. 10.1001\/archderm.135.5.574","journal-title":"Arch Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1076\/ocii.6.1.51.8079","article-title":"Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis","volume":"6","author":"Whitcup SM","year":"1998","unstructured":"Whitcup SM, Pleyer U, Lai JC, Lutz S, Mochizuki M, Chan CC. Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis. Ocul Immunol Inflamm. 1998, 6:51-6. 10.1076\/ocii.6.1.51.8079","journal-title":"Ocul Immunol Inflamm"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000151507.49565.6e","article-title":"Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders","volume":"24","author":"Joseph MA","year":"2005","unstructured":"Joseph MA, Kaufman HE, Insler M. Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea. 2005, 24:417-20. 10.1097\/01.ico.0000151507.49565.6e","journal-title":"Cornea"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.07.025","article-title":"Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases","volume":"115","author":"Miyazaki D","year":"2008","unstructured":"Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, Nagata Y, Hasegawa J, Inoue Y. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology. 2008, 115:988-92.e5. 10.1016\/j.ophtha.2007.07.025","journal-title":"Ophthalmology"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e318159afbb","article-title":"Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis","volume":"27","author":"Kymionis GD","year":"2008","unstructured":"Kymionis GD, Goldman D, Ide T, Yoo SH. Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis. Cornea. 2008, 27:228-9. 10.1097\/ICO.0b013e318159afbb","journal-title":"Cornea"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2006.00699.x","article-title":"Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study","volume":"84","author":"Virtanen HM","year":"2006","unstructured":"Virtanen HM, Reitamo S, Kari M, Kari O. Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. Acta Ophthalmol Scand. 2006, 84:693-5. 10.1111\/j.1600-0420.2006.00699.x","journal-title":"Acta Ophthalmol Scand"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.10.065","article-title":"Vernal keratoconjunctivitis: result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment","volume":"113","author":"Vichyanond P","year":"2004","unstructured":"Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P, Jirapongsananuruk O, Visitsunthorn N, Kosrirukvongs P. Vernal keratoconjunctivitis: result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment. J Allergy Clin Immunol. 2004, 113:355-8. 10.1016\/j.jaci.2003.10.065","journal-title":"J Allergy Clin Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0087","article-title":"A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis","volume":"26","author":"Ohashi Y","year":"2010","unstructured":"Ohashi Y, Ebihara N, Fujishima H, et al.. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2010, 26:165-74. 10.1089\/jop.2009.0087","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31822481c2","article-title":"Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis","volume":"31","author":"Tzu JH","year":"2012","unstructured":"Tzu JH, Utine CA, Stern ME, Akpek EK. Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis. Cornea. 2012, 31:649-54. 10.1097\/ICO.0b013e31822481c2","journal-title":"Cornea"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2011.75","article-title":"Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis","volume":"25","author":"Kheirkhah A","year":"2011","unstructured":"Kheirkhah A, Zavareh MK, Farzbod F, Mahbod M, Behrouz MJ. Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis. Eye (Lond). 2011, 25:872-80. 10.1038\/eye.2011.75","journal-title":"Eye (Lond)"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0803","article-title":"One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial","volume":"90","author":"Mandelin J","year":"2010","unstructured":"Mandelin J, Remitz A, Virtanen H, Reitamo S. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial. Acta Derm Venereol. 2010, 90:170-4. 10.2340\/00015555-0803","journal-title":"Acta Derm Venereol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181d83875","article-title":"Topical tacrolimus ointment for treatment of intractable atopic keratoconjunctivitis: a case report and review of the literature","volume":"30","author":"Garc\u00eda DP","year":"2011","unstructured":"Garc\u00eda DP, Alperte JI, Crist\u00f3bal JA, et al.. Topical tacrolimus ointment for treatment of intractable atopic keratoconjunctivitis: a case report and review of the literature. Cornea. 2011, 30:462-5. 10.1097\/ICO.0b013e3181d83875","journal-title":"Cornea"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.12.009","article-title":"Application for tacrolimus ointment in treating refractory inflammatory ocular surface diseases","volume":"155","author":"Lee YJ","year":"2013","unstructured":"Lee YJ, Kim SW, Seo KY. Application for tacrolimus ointment in treating refractory inflammatory ocular surface diseases. Am J Ophthalmol. 2013, 155:804-13. 10.1016\/j.ajo.2012.12.009","journal-title":"Am J Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/190495-treatment-of-steroid-resistant-nodular-episcleritis-with-tacrolimus-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:10Z","timestamp":1707509350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/190495-treatment-of-steroid-resistant-nodular-episcleritis-with-tacrolimus-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,15]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.47057","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,15]]}}}